- COVID-19 infection increases risk of a range of neurological diseases,
- Cancer patients eating ice cream can reduce this side effect of chemotherapy
- Gut microbes may become a new therapy for depression and anxiety
- The risk of Alzheimer’s disease increases by 50-80% within a year after COVID-19 infection
- Hong Kong will launch monkeypox vaccination for high-risk groups in October
- Ebola (Sudan strain) outbreak in Uganda
Uzbekistan approved Chinese recombinant protein subunit COVID-19 vaccine
Uzbekistan approved Chinese recombinant protein subunit COVID-19 vaccine. The new coronavirus recombinant protein subunit vaccine developed by the team of Academician Gao Fu is launched in Uzbekistan.
The new coronavirus recombinant protein subunit vaccine jointly developed by the Gao Fu team of the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd. was approved for use in Uzbekistan (Figure 1), and immunization started this month). Uzbekistan evaluates this vaccine as one of the safest and most effective vaccines in the world!
Figure 1. China’s new coronavirus recombinant protein subunit vaccine was approved in Uzbekistan
Recombinant protein subunit vaccine is a vaccine prepared by expressing the key antigen protein of the virus in an in vitro recombinant manner. The research and development of the new coronavirus recombinant protein subunit vaccine is mainly aimed at the development of vaccines against the receptor binding domain (RBD region) on the S protein of the new coronavirus.
The Gao Fu team of the Institute of Microbiology, Chinese Academy of Sciences and Anhui Zhifei Longkoma Biopharmaceutical Co., Ltd., under the leadership of Gao Fu, expressed the dimer protein of two new coronavirus RBDs in tandem to prepare a recombinant protein subunit vaccine (Figure 2) 1. The results of animal experiments and clinical trials have shown good safety and protection. 2.
It is worth mentioning that the research team tested the neutralizing effect of the vaccine against the COVID-19 mutant strains (South Africa strain and British strain), and preliminary results show that the vaccine is still effective against the COVID-19 mutant3.
Figure 2. General vaccine strategy for β-coronavirus 1
The vaccine has independent intellectual property rights. At present, the vaccine has undergone phase III clinical trials in Uzbekistan and has been approved for use. Immunization will begin this month. This vaccine became the fifth Chinese-made new coronavirus vaccine approved for marketing (Figure 3).
Figure 3. Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd. Recombinant New Coronavirus Vaccine
From the perspective of vaccine production, the production process of recombinant protein vaccine is relatively simple. It does not need to inactivate the whole virus. It only needs to recombinantly express effective antigen fragments in vitro. Therefore, it can be produced in a general-level biosafety laboratory, which significantly reduces the production of vaccines. Cost, and the production capacity is large, storage and transportation are more convenient.
(source:internet, reference only)